SYMPATICO: efficacy and safety of ibrutinib plus venetoclax in treatment-naive MCL

Michael Wang, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the treatment-naive cohort in the SYMPATICO clinical trial (NCT03112174), a multi-center study that investigated the efficacy of a combination of ibrutinib and venetoclax in mantle cell lymphoma (MCL). Prof. Wang highlights the trial's impressive results, making this combination therapy is particularly beneficial for older patients with comorbidities who may not be suitable candidates for chemotherapy. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Видео SYMPATICO: efficacy and safety of ibrutinib plus venetoclax in treatment-naive MCL канала VJHemOnc – Video Journal of Hematology & HemOnc